Pay in 4 interest-free payments of $5.52 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
There are dozens of ongoing clinical trials exploring: New molecules : Next-generation GLP-1 agonists with longer duration, better safety, or oral administration (several oral semaglutide competitors are in trials)
Warfarin INR may fluctuate during tirzepatide titration
In some cases, telehealth execs are pivoting to strike a deal with pharmaceutical companies
Tirzepatide is a once-weekly injectable that activates both GLP-1 and GIP receptors
KEY TAKEAWAYS GLP-1 medications require individualized medical evaluation, not one-size-fits-all prescribing Direct-to-consumer microdosing platforms lack FDA approval and proper medical oversight The erosion of trust in healthcare has created opportunities for unregulated treatments Comprehensive metabolic care includes regular lab work, body composition monitoring, and personalized treatment plans Technology should enhance medical care, not replace proper physician evaluation NOTABLE QUOTE "I see so many people that come in, you know, they're obsessed with monitoring their HRV, their heart rate variability, and yet they had no idea they have pre-diabetes and they had no idea that they have triglyceride levels through the roof." Dr
Lower Reward-Drive Inside the Brain GLP-1 acts directly in the nucleus accumbens (reward center): food feels less urgent reward-seeking decreases the pull of cravings weakens This explains why people report: less binge eating less drinking less smoking less late-night snacking fewer random cravings overall When the Glucose Curve Stays Stable, Everything Calms Down stress reactivity drops impulsive actions decrease reward seeking slows emotional eating reduces hangry episodes disappear nervous system volatility decreases GLP-1 makes regulation possible again not psychologically, but metabolically
